Table 3.

GeneScreen 5-FU assessment schedule

Assessment Time-point	Data points collected	Comments
Baseline	Patient and cancer demographics FP chemotherapy data DPYD genotype status	FP containing regimens Chemotherapy indication
Post-first FP dose	Patient metrics FP dose and adjustments FP related toxicities Hospitalisations, ICU admissions, treatment-related death	G3-4 toxicities Time in hospital Time in ICU G5 toxicity-related deaths Dose reduction data
Subsequent FP administration (capped at 60 days post-first dose)	Patient metrics FP dose and adjustments FP related toxicities Hospitalisations, ICU admissions, treatment-related death	G3-4 toxicities Time in in hospital Time in ICU G5 toxicity-related deaths Dose reduction data
No fixed time point	Patient and clinician semi-structured interviews	Exploration of patient/clinician experience of genotyping process Clinician satisfaction with education/support resources, facilitators/barriers to ongoing use
Follow-up	Cancer outcomes reports at 6-month intervals up to 5 years post-FP	Disease-free survival (DFS) Progression-free survival (PFS) Overall survival (OS) All cause mortality